F. Kawasaki’s Disease
  • Barry L. Myones


  • Kawasaki’s disease (KD), once known as mucocutaneous lymph node syndrome, is a systemic inflammatory disorder occurring in children that is accompanied by vasculitis and a risk of coronary artery aneurysms.

  • Other typical features of KD include spiking fevers, cervical lymphadenopathy, conjunctivitis, erythematous changes on the lips and in the oral cavity, dryness and cracking of the lips, a strawberry appearance to the tongue, and a polymorphous rash.

  • Eighty percent of KD cases occur in children less than 5 years of age.

  • Attempts to link KD definitively to some types of infection, particularly ones associated with superantigens, have thus far been unsuccessful.

  • High dose aspirin and intravenous immune globulin (IVIG) are the cornerstones of therapy in KD. IVIG is essential to the prevention of coronary aneurysms.

  • ■ Years after KD has occurred during childhood years, some cases of myocardial infarction caused by thrombosis of coronary aneurysms have been reported.


Kawasaki Disease American Heart Association Rheumatic Fever Coronary Artery Aneurysm Coronary Artery Abnormality 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children [in Japanese]. Arerugi 1967;16:178–222.PubMedGoogle Scholar
  2. 2.
    Kawasaki T, Kosaki F, Okawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54:271–276.PubMedGoogle Scholar
  3. 3.
    Takahashi M. Kawasaki syndrome (mucocutaneous lymph node syndrome). In: Emmanouilides GC, ed. Moss and Adams heart disease in infants, children, and adolescents: including the fetus and young adult. 5th ed. Baltimore: Williams & Wilkins, 1995:13909.Google Scholar
  4. 4.
    Spector S. Scarlett fever, periarteritis nodosa, aneurysm of the coronary artery with spontaneous rupture, hemopericardium. Arch Pediatr 1939;25:319.Google Scholar
  5. 5.
    Kato H, Ichinose E, Yoshioka F, et al. Fate of coronary aneurysms in Kawasaki disease: serial coronary angiography and long-term follow-up study. Am J Cardiol 1982;49:1758–1766.PubMedCrossRefGoogle Scholar
  6. 6.
    Kato H, Ichinose E, Kawasaki T. Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. J Pediatr 1986;108:923–927.PubMedCrossRefGoogle Scholar
  7. 7.
    Japan Kawasaki Disease Research Committee. Diagnostic guideline of Kawasaki disease. Tokyo: Japan Kawasaki Disease Research Committee; 1984.Google Scholar
  8. 8.
    American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease. Diagnostic guidelines for Kawasaki disease. Am J Dis Child 1990;144:1218–1219.Google Scholar
  9. 9.
    Dajani AS, Taubert KA, Gerber MA, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993;87:1776–1780.PubMedGoogle Scholar
  10. 10.
    Rowley AH, Gonzalez-Crussi F, Gidding SS, et al. Incomplete Kawasaki disease with coronary artery involvement. J Pediatr 1987;110:409–413.PubMedCrossRefGoogle Scholar
  11. 11.
    Rosenfeld EA, Corydon KE, Shulman ST. Kawasaki disease in infants less than one year of age. J Pediatr 1995;126:524–529.PubMedCrossRefGoogle Scholar
  12. 12.
    Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long term management of Kawasaki disease. A statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease. Council on cardiovascular disease in the young. American Heart Association. Circulation 2004;110:2747–2771.PubMedCrossRefGoogle Scholar
  13. 13.
    Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long term management of Kawasaki disease. A statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease. Council on cardiovascular disease in the young. American Heart Association. Pediatrics 2004;114:1708–1733.PubMedCrossRefGoogle Scholar
  14. 14.
    Taubert KA. Epidemiology of Kawasaki disease in the United States and worldwide. Prog Pediatr Cardiol 1997;6:181–185.CrossRefGoogle Scholar
  15. 15.
    Mason WH, Takahashi M, Schneider T. Recurrence of Kawasaki disease in a large urban cohort in the United States. In: Takahashi M, Taubert K, eds. Proceedings of the Fourth International Symposium on Kawasaki Disease. Dallas: American Heart Association; 1993:21–26.Google Scholar
  16. 16.
    Taubert KA, Rowley AH, Shulman ST. A 10 year (1984-1993) United States hospital survey of Kawasaki disease. In: Kato H, ed. Kawasaki disease: proceedings of the 5th International Kawasaki Disease Symposium. New York: Elsevier; 1995:34–38.Google Scholar
  17. 17.
    Yanagawa H, Yashiro M, Nakamura Y, et al. Results of 12 nationwide epidemiological incidence surveys of Kawasaki disease in Japan. Arch Pediatr Adolesc Med 1995;149:779–783.PubMedGoogle Scholar
  18. 18.
    Barron KS, Shulman ST, Rowley A, et al. Report of the National Institutes of Health workshop on Kawasaki disease. J Rheumatol 1999;26:170–190.PubMedGoogle Scholar
  19. 19.
    Leung DY, Meissner HC, Shulman ST, et al. Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease. J Pediatr 2002;140:742–746.PubMedCrossRefGoogle Scholar
  20. 20.
    Leung DYM, Giorno RC, Kazemi LV, et al. Evidence for superantigen involvement in cardiovascular injury due to Kawasaki disease. J Immunol 1995;155:5018–5021.PubMedGoogle Scholar
  21. 21.
    Leung DY, Meissner HC, Fulton DR, et al. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993;342:1385–1388.PubMedCrossRefGoogle Scholar
  22. 22.
    Abe J, Kotzin BL, Jujo K, et al. Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc Natl Acad Sci USA 1992;89:4066–4070.PubMedCrossRefGoogle Scholar
  23. 23.
    Tomita S, Myones BL, Shulman ST. In vitro correlates of L. casei animal model of Kawasaki Disease. J Rheumatol 1993;20:362–367.PubMedGoogle Scholar
  24. 24.
    Duong TT, Silverman ED, Bissessar MV, et al. Superantigenic activity is responsible for induction of coronary arteritis in mice: and animal model for Kawasaki disease. Int Immunol 2003;15:79–89.PubMedCrossRefGoogle Scholar
  25. 25.
    Rowley AH, Eckerley CA, Jack HM, et al. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol 1997;159:5946–5955.PubMedGoogle Scholar
  26. 26.
    Rowley AH, Shulman ST, Spike BT, et al. Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J Immunol 2001;166:1334–1343.PubMedGoogle Scholar
  27. 27.
    Laxer RM, Schaffer FM, Myones BL, et al. Lymphocyte abnormalities and complement activation in Kawasaki disease. Prog Clin Biol Res 1987;250:175–184.PubMedGoogle Scholar
  28. 28.
    Myones BL, Bathori JM, Tomita S, et al. Intravenous IgG infusions are associated with the in vitro inhibition of classical pathway-mediated lysis of sheep red blood cells and a decrease in C4d levels in Kawasaki disease. In: Takahashi M, Taubert K, eds. Proceedings of the Fourth International Kawasaki Disease Symposium. Dallas: American Heart Association; 1993:412–418.Google Scholar
  29. 29.
    Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888–893.PubMedCrossRefGoogle Scholar
  30. 30.
    Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984;2:1055–1058.PubMedCrossRefGoogle Scholar
  31. 31.
    Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341–347.PubMedCrossRefGoogle Scholar
  32. 32.
    Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633–1639.PubMedCrossRefGoogle Scholar
  33. 33.
    Dajani AS, Taubert KA, Takahashi M, et al. Guidelines for long-term management of patients with Kawasaki disease. Circulation 1994;89:916–922.PubMedGoogle Scholar
  34. 34.
    Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63:175–179.PubMedGoogle Scholar
  35. 35.
    Wright DA, Newburger JW, Baker A, et al. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128:146–149.PubMedCrossRefGoogle Scholar
  36. 36.
    Shinohara M, Sone K, Tomomasa T, et al. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr 1999;135:465–469.PubMedCrossRefGoogle Scholar
  37. 37.
    Hashino K, Ishii M, Iemura M, et al. Re-treatment of immunoglobulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001;43:211–217.PubMedCrossRefGoogle Scholar
  38. 38.
    Sundel RP, Baker AL, Fulton DR, et al. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003;142:611–616.PubMedCrossRefGoogle Scholar
  39. 39.
    Myones BL, Altman CA, Ayres N, et al. Imaging of coronary and peripheral arteries with magnetic resonance angiography (MRA) in infants with Kawasaki disease: a new utilization to guide therapy. Arthritis Rheum 2002;46: S309.CrossRefGoogle Scholar
  40. 40.
    Furukawa S, Matusubara T, Umezawa Y, et al. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease. Eur J Pediatr 1994;153:664–667.CrossRefGoogle Scholar
  41. 41.
    Best BM, Burns JC, DeVincenzo J, et al. Pharmacokinetics and tolerablility assessment of a pediatric oral formulation of pentoxifylline in Kawasaki disease. Curr Ther Res 2003;64:96–115.CrossRefGoogle Scholar
  42. 42.
    Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki Syndrome. J Pediatr 2005;146:662–667.PubMedCrossRefGoogle Scholar
  43. 43.
    Weiss JE, Eberhard BA, Chowdhury D, et al. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004;31:808–810.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Barry L. Myones
    • 1
  1. 1.Pediatric Rheumatology CenterBaylor College of Medicine/Texas Children’s HospitalHoustonUSA

Personalised recommendations